A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC)

Trial Profile

A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Carotuximab (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 May 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 10 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 24 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top